Avid Bioservices Inc (CDMO)

[nuke661]

md,

What I find more interesting is that Thorpe is going to present (apparently no matter if there is or isn't any public update on the 2nd line trial data by Dec 5) that:

Bavituximab is a monoclonal antibody that is proving safe and effective as a second-line therapy in advanced lung cancer patients.

I would think that Peregrine would have to take responsibility for the veracity of that statement. Letting Dr. Thorpe make that statement seems to be a big risk in the current climate unless Peregrine is confident that they are going to be able to back that statement up. Of course the legal profession can parse the hell out of what "effective" means in this context which I'm sure will take into account the actual statements made by Dr. Thorpe on Dec 5.